Nationwide availability gives healthcare providers and patients a new treatment option
San Francisco, CA (UroToday.com) — Urovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, announced the commercial launch of GEMTESA® (vibegron) 75 mg tablets, a beta-3 (β3) adrenergic receptor agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults.